Table 5.
Summary of studies in the literature reporting EARs associated with QSMI antivenoms.
| Reference (Study Period) |
Total Snakebite Patients | Type of Antivenom Used |
Incidence of EARs % |
Severe EARs % |
|---|---|---|---|---|
| Fung et al. [43] (2000–2005) |
192 | Cobra, GPV, KC | 0 | 0 |
| Thiansookon et al. [11] (1997–2006) |
382 | Cobra, GPV, MPV, RV | 3.5 | 1.6 |
| Blessmann et al. [44] (2007–2008) |
21 | MPV | 0 | 0 |
| Vongphoumy et al. [17] (2007–2008) |
158 | Cobra, GPV, MK, MPV, HPAV, NPAV | 53.0 | 30.0 |
| Mong et al. [18] (2008–2015) |
191 | GPV | 4.7 | 1.6 |
| Tongpoo et al. [4] (2008–2016) |
78 | BK, Cobra, MK, NPAV | 6.0 | 0 |
| Kraisawat and Promwang [42] (2006–2017) |
153 | MPV, HPAV | 8.0 | 0 |
EARs; early adverse reactions, BK; banded krait, GPV; green pit viper, HPAV; Hemato polyvalent antivenom, KC; king cobra, MK; Malayan krait, MPV; Malayan pit viper, NPAV; Neuro polyvalent antivenom, RV; Russell’s viper.